MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

Exclusion Criteria

• •1. Recent or current use of glucocorticoid or other immunosuppressor or Drug that stimulates bone marrow hematopoiesis;
• •2. Uncontrolled systemic active infection: fungi, bacteria, viruses or other infections;
• •3. Active infection with HBV, HCV or HIV;
• •4. Patients with symptoms and disease history of central nervous system;
• •5. Pregnant or lactating female；The patient did not agree to use effective contraception during the treatment period and for the following 1 year；
• •6. Patients receiving allogeneic hematopoietic stem cell transplantation, or organ transplantation
• •7. A history of other malignant tumors;
• •8. Primary immunodeficiency disease, or autoimmune disease;
• •9. Patients treated with PD-1 inhibitors or PD-L1 inhibitors prior to enrollment;
• •10. Patients who participated in other clinical trials within 4 weeks before blood collection;
• •11. Patients who had used CD19 targeted therapy before enrollment;
• •12. The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study.